CQDM is organized according to a unique public-private partnership model for the funding and development of innovative research activities, primarily of a precompetitive nature, where the needs of the pharmaceutical industry are at the focus of the research agenda.
This model will allow the public sector and the pharmaceutical industry to invest more in R&D and increase the productivity of their investments in Canada.
CQDM promotes the creation of synergy between academic research and industrial research. This synergy stems from the creation of a network for exchange and cooperation in research at universities, hospitals, biotechnology companies and the broader pharmaceutical industry. The network offers all stakeholders the opportunity to identify the partners who are best suited to the pursuit of common objectives.
Regulatory agencies and pharmaceutical industries in all of the world’s countries recognize the need to translate scientific innovations into new therapeutic breakthroughs more efficiently. Initiatives in this regard are already being undertaken in the United States, Europe and the rest of the world, and they are all looking to a new model for cooperation between regulatory agencies, the industry, patients and the academic milieu.
CQDM’s model is perfectly suited to this trend because it has a unique characteristic: the dynamic and ongoing presence of the academic milieu in addition to the active role played by government agencies and the industry. In the United States and Europe, university researchers simply respond to calls for proposals, while under CQDM’s model, they are part of a driving force.